Cargando…

2270. Initial Treatment Selection Among Patients with Recurrent Pseudomonas aeruginosa (PSA) Infections (Infxs): Does Prior PSA Antibiotic Susceptibility Results Effect Subsequent Empiric Treatment Decisions?

BACKGROUND: Resistance to commonly used anti-pseudomonal β-lactams (AP-BLs) like piperacillin/tazobactam (TZP), meropenem (MER) and cefepime (CEF) among patients (patients) with PSA infx is increasing. To minimize receipt of DAT among patients with PSA infxs, clinicians need to consider the patient’...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puzniak, Laura, Gupta, Vikas, Dillon, Ryan J, Yu, Kalvin, Murray, John, Lodise, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809578/ http://dx.doi.org/10.1093/ofid/ofz360.1948

Ejemplares similares

1596. Ceftolozane/tazobactam (Zerbaxa) for the Treatment of Pseudomonas aeruginosa (PSA) Bacteremia: A Systematic Literature Review (SLR)
por: Dillon, Ryan J, et al.
Publicado: (2020)

1601. Evaluation of Synergy with β-Lactams Plus Aztreonam Against Pseudomonas aeruginosa (PSA)
por: O’Donnell, J Nicholas, et al.
Publicado: (2019)

786. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) From 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

1184. Activity of anti-pseudomonal antibiotics among all Pseudomonas aeruginosa (PSA) at an academic medical health system, including β-lactam, multi-drug (MDR) and extensively drug resistant (XDR) strains
por: Rose, Warren, et al.
Publicado: (2020)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

1623. Outcomes of Critically Ill Adults, Hospitalized Patients (Pts) with Pseudomonas aeruginosa (PSA) Hospital- and Ventilator-Associated Pneumonia (HAP/VAP) Who Received an Active Anti-Pseudomonal β-Lactam (ASPB): Does “S” Equal Success in the Presence of Resistance to other ASPB?
por: Lodise, Thomas, et al.
Publicado: (2020)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model
por: Chen, Iris H, et al.
Publicado: (2020)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
por: McGagh, Dylan, et al.
Publicado: (2020)

PSA 1972 : proceedings of the 1972 biennial meeting philosophy of science association
Publicado: (1974)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against pseudomonas Aeruginosa (psa) from Patients with Cystic Fibrosis (CF)
por: Lasko, Maxwell J, et al.
Publicado: (2020)

Theory of stellar pulsation (PSA-2)
por: Cox, John P
Publicado: (2017)

Multiparametric MRI in the PSA Screening Era
por: George, Arvin K., et al.
Publicado: (2014)

Fasting times in serum PSA assay
por: Xu, Xiang, et al.
Publicado: (2014)

PSA mass screening: is there enough evidence?
por: Rocco, Bernardo, et al.
Publicado: (2012)

Rheological and Mechanical Properties of an Acrylic PSA
por: Simões, Beatriz D., et al.
Publicado: (2023)

Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia
por: Caffrey, Aisling R., et al.
Publicado: (2022)

Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity
por: Mattsson, Johanna M., et al.
Publicado: (2014)

Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
por: Frasca, Loredana, et al.
Publicado: (2018)

PsaF Is a Membrane-Localized pH Sensor That Regulates psaA Expression in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2021)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

1628. Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia
por: Caffrey, Aisling, et al.
Publicado: (2020)

Pretreatment PSA levels affects the completion rate of Ra-223 treatment
por: Utsumi, Nobuko, et al.
Publicado: (2021)

1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against Pseudomonas aeruginosa (PSA) from Patients with Cystic Fibrosis (CF)
por: Lasko, Maxwell J, et al.
Publicado: (2020)

A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate Cancer
por: Gentile, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mi3d5b83l20lo68obf5drurg1o